Drugs / Human CD19Targeted T Cells Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05436223 | Aug 2021 → Aug 2024 overdue | B-cell non-Hodgkin lymphoma | Hrain Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human CD19Targeted T Cells Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05436223 ↗ |
| Modality | Cell therapy | “CD19 CAR+ T cells” NCT05436223 ↗ |
| Target | CD19 | “Human CD19 Targeted T Cells Injection” NCT05436223 ↗ |